Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.13 +0.19 (+0.76%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Election Outcome Presents Opportunity For Investors
Let’s break down the key sectors that stand to gain from a Trump or Harris presidency and explore the risks investors should be aware of heading into this election outcome. 
Via Talk Markets
Topics Government
Exposures Political
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
Via The Motley Fool
Behind the Scenes of Pfizer's Latest Options Trends
Via Benzinga
Key Takeaways From Pfizer Analyst Ratings
Via Benzinga
Pfizer Unusual Options Activity
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
Via Benzinga
3 Stocks Set to Benefit from Cooling Inflation Trends
Three stocks stand out in the way they can outperform the rest of the industry despite a slowing inflation rate in the economy, with high income 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Is Pfizer a Buy Right Now or a Value Trap?
Pfizer has prepared for today's challenges... and has set big goals. 
Via The Motley Fool
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding... 
Via Benzinga
3 Sensational Ultrahigh-Yield Dividend Stocks That Make for No-Brainer Buys in the 4th Quarter (and Beyond)
Three high-octane income stocks -- sporting an average yield of 6.23% -- have the necessary tools and intangibles to make their patient shareholders richer. 
Via The Motley Fool
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You?
A 5.8% forward-dividend yield is just one reason the hedge fund manager likes this stock. 
Via The Motley Fool
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
Exposures COVID-19
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company. 
Via Benzinga
Top 3 Discounted Value Stocks Worth Buying Now
These stocks have a large cushion while retaining intrinsic value. 
Via Talk Markets
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
Exposures Product Safety
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
Exposures COVID-19
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks might look like bad picks. But appearances can be deceiving. 
Via The Motley Fool
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Pfizer has withdrawn Oxbryta from global markets and halted all clinical trials, citing safety concerns following clinical data that raised issues about fatal complications in sickle cell disease... 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
These two high-yield dividend stocks should deliver steady passive income for years to come. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Consider these three for a combination of dividend growth and a high yield. 
Via The Motley Fool
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
One of these is not like the other. 
Via The Motley Fool
3 Ultra-Cheap Stocks That Could Get a Boost From Fed Rate Cuts
These stocks are all trading at less than 12 times their estimated future earnings. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.